Takeda buys US drug-developer Syrxx
Friday, 11 February, 2005
Japanese pharmaceutical giant Takeda has paid US$270 million in cash to acquire Syrxx, a private drug-development company based in San Diego.
Syrxx is a specialist in high-throughput X-ray crystallography, which it uses to design therapeutics to treat metabolic diseases, cancer, and inflammation. It has several compounds for type 2 diabetes in preclinical and early clinical trials.
Takeda is under pressure to use its cash balance of over 1 trillion yen to fill its poor drug development pipeline. It halted development of a promising diabetes drug late last year.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
